Wednesday, February 17, 2016 9:57:35 AM
We employ our Ligand Activated Therapy (LAT) platform technology to create prodrugs in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
Our most advanced product candidate, KP201/APAP, consists of KP201, our prodrug of hydrocodone, formulated in combination with acetaminophen (APAP). We are developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute moderate to moderately severe pain.
KP201/APAP was designed with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. We designed KP201/APAP to deter tampering and abuse by selecting a molecular structure that prevents the release of the opioid upon crushing, physical manipulation and other commonly employed extraction techniques. We believe this approach to abuse-deterrence at the molecular level may be more effective than many formulation-based abuse-deterrence technologies, which combine the opioid drug with another drug or use an abuse-deterrent capsule or physical matrix.
In addition to KP201/APAP, KemPharm is building a pipeline of prodrug product candidates that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.
Recent KMPH News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 11:49:38 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/10/2024 08:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 11:46:20 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/09/2024 04:15:27 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/03/2024 08:17:44 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2024 08:15:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2024 09:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/30/2023 08:14:13 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM